Conventional paints present notable health and environmental hazards due to the presence of heavy metal-based pigments and the emission of volatile organic compounds (VOCs) from synthetic binders. Prior research has shown that genetically engineered microorganisms, such as Escherichia coli, can biosynthesize pigments that offer reduced environmental impact. However, biologically derived pigments to date have been formulated with VOC-emitting binders. Casein, a natural, VOC-free binder used since antiquity, represents a promising alternative, though its compatibility with biologically derived pigments has not been systematically evaluated. Bacterial pigments and protein binders are sustainable because they are derived from renewable biological sources. This study investigates a novel paint formulation combining E. coli–derived pigment with a casein-based binder and compares its spectral durability to two mineral-based commercial paints under varied environmental conditions. Spectral intensity analysis demonstrated that biologic paint retained color stability comparable to both commercial standards; although four statistically significant differences were observed, all were below the threshold of human visual perception. These results demonstrate that coupling biologically derived pigments with a casein binder can yield an effective, environmentally safer alternative to conventional paint systems.
To compare clinical outcomes, complications, and long-term graft survival following penetrating keratoplasty (PK) versus deep anterior lamellar keratoplasty (DALK) in keratoconus, with 10 years of follow-up. This retrospective, comparative cohort study included 224 consecutive primary grafts performed for keratoconus, each with a minimum follow-up of 10 years. Of these, 116 eyes underwent PK and 108 eyes underwent DALK. Outcome measures included postoperative visual acuity, refractive error, and postoperative complications. Graft survival at 10 and 15 years was also evaluated. The mean follow-up was 11.7 ± 1.4 years in the PK group and 11.4 ± 1.6 years in the DALK group (P = 0.10). Final visual acuity and refractive error were similar between groups; however, PK resulted in faster visual recovery and a higher proportion of eyes achieving corrected distance visual acuity (CDVA) ≥ 20/25. Episodes of graft rejection were more frequent after PK, with 10-year rejection-free survival rates of 66.4
Image-derived artificial intelligence (AI) risk models have shown promise in short-term risk assessment for improving breast cancer (BC) screening. No image-derived long-term AI risk model for primary prevention has been developed and externally validated. Individuals aged 31 to 94 years were recruited between 2010 and 2020 in two population-based case cohorts (Olmsted County, Minnesota, US, and KARMA, Sweden) and one hospital-based case-control study (EMBED, Atlanta, US). Median follow-up in the case cohorts was 10 years, with BCs diagnosed through June 2022. Additional validation was performed in EMBED with 3-year follow-up. An AI risk model was developed in Sweden, and we report independent validation in Olmsted/KARMA/EMBED. Absolute 10-year risks were estimated at study entry. Time-dependent discriminatory performance [AUC(t)] and expected-to-observed events (E/O) were estimated. Comparisons were performed with clinical risk tools and the image-based Mirai tool. Across Olmsted/KARMA, 8696 individuals (mean age, 54.4±10.6) and 1633 individuals with incident BC (mean age, 57.0±10.6) were included. Average 10-year risks were 3.83 and 3.14%, and E/O ratios were 0.99 and 0.99. Ten-year AUC(t) for invasive BCs were 0.72 in Olmsted and 0.72 in KARMA. Similar discriminatory results were observed in EMBED. Our AI risk tool performed significantly better than Mirai in Olmsted/KARMA/EMBED. In KARMA, in the top 10% of high-risk individuals, the AI risk tool predicted 33% of BCs compared with 23%/20%/24% predicted by Tyrer-Cuzick-v8/BCSC-v3/Mirai (all P < 0.01). The 10-year image-derived AI risk model showed significantly higher performance than clinical risk models and Mirai in diverse populations, supporting its clinical potential for primary prevention.
Summary Background: Genetic risk scores (GRS) for type 1 diabetes (T1D) have been developed primarily in European populations, limiting their generalisability across ancestries. Indians differ from Europeans in clinical characteristics of T1D and overall genetic architecture, yet systematic evaluation of T1D GRS performance in multi-regional Indian cohorts is lacking. Methods: The study included 597 T1D patients and 3347 non-diabetic controls from different regions in India. Genotyping, imputation, quality control analysis, and construction of the 67-SNPs T1D GRS were performed using standardised pipelines. Discriminative performance was assessed using Receiver Operative Curve-Area under Curve (ROC-AUC) analysis, and optimal thresholds were derived using Youden's index. HLA-DQ diplotype frequencies were compared, and association analysis was conducted using multivariable logistic regression. Findings: T1D GRS showed consistent discriminative performance across Indian cohorts [ROC-AUC=0.84 (range=0.78-0.87)], supporting its comprehensive use for T1D classification in India. Notably, its performance was lower in islet cell autoantibody (IA) negative compared with IA positive T1D patients (ROC-AUC, 0.75 vs 0.85) and in adult-onset than in childhood-onset patients (0.74 vs 0.84). We observed a lower frequency of protective HLA-DQ diplotypes and a strong association of HLA-DQ81 containing diplotypes in childhood-onset T1D. Application of an India-specific T1D GRS score improved the sensitivity than the European cut-off. Interpretation: T1D GRS is a valuable unified diagnostic tool in Indians, but its performance varies by islet cell autoantibody status and age at onset, likely reflecting population-specific HLA architecture. European-derived T1D GRS thresholds under-classify the genetic risk, highlighting the importance of ancestry-aware optimisation in Indians. Funding: CDRC grant CDRC202111026 and CSIR Intramural Grant P50. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement The study was funded by Chellaram Diabetes and Research Centre (CDRC), Pune, India (CDRC grant CDRC202111026) and the Council of Scientific and Industrial Research (CSIR), Ministry of Science and Technology, Government of India, New Delhi, India (CSIR Intramural Grant P50). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The collection of clinical data and use of bio-banked samples for the biochemical, immunological, and genetic measurements was sanctioned by the Ethics committee of the respective collaborating institutes. CSIR-CCMB (IEC-92/2022), TDRC (IHEC-TDRC-HYD/1/2022), CDI (CDI/BR/2024/058), JSS (JSSMC/IEC/19052022/01NCT/2022-23), OSM (IEC-BHR/OMC/M.NO(07)/P-89). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Requests to data access should be submitted to the corresponding author Dr. Giriraj R. Chandak (chandakgrc.ccmb{at}csir.res.in).